Nasdaq
$10.34▲ 1.62%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $592.1MShares out 57.3M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
7- 1d agoAfter-hours26.10.24 06:268-KKey event#●●●#●●●
Climb Bio, Inc.Bullish
Climb Bio announced additional Phase 1 clinical data for its IgA nephropathy candidate, CLYM116, showing a ~70% reduction in Gd-IgA1 and an estimated 33-day half-life at an 800 mg dose. The company is currently enrolling patients in the NAVIGATE-2 Phase 2 trial, with initial data expected in the first half of 2027.…more
$10.34+1.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.30After-hours26.10.01 05:554Ownership
Climb Bio, Inc.
RA Capital Management and its affiliated funds, as major shareholders of Climb Bio, Inc., have filed a Form 4 to report changes in their beneficial ownership of securities as of September 28, 2026. This filing serves to notify the market of equity adjustments by insiders and major stakeholders.…more
$10.34+1.62%vs prev closeView filingShare - 9.17After-hours26.09.18 05:154Ownership
Climb Bio, Inc.
Insider Thomas Stephen Basil of Climb Bio, Inc. filed a Form 4 statement of changes in beneficial ownership of securities on September 15, 2026. This filing formalizes the changes in the insider's equity holdings.…more
$10.34+1.62%vs prev closeView filingShare
6 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 12h agoClosed26.10.25 08:30#●●●#●●●
Climb Bio Announces Initial Phase 2 Data for Budoprutug in pMN
Climb Bio reported positive initial Phase 2 clinical data for its budoprutug treatment, demonstrating B-cell depletion and immunologic remission in patients with primary membranous nephropathy. While the results are encouraging, the company continues to enroll patients for further evaluation and data collection.…more
$10.34+1.62%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 1d agoAfter-hours26.10.24 05:01
●●●●●●●● ●●●●● ●●●●●●
Climb Bio announced positive Phase 1 results for its IgA nephropathy candidate, CLYM116, demonstrating sustained efficacy that supports a 12-week dosing interval. The company is currently enrolling patients for a Phase 2 trial and expects to initiate a global Phase 3 study in 2027.…more
$10.34+1.62%vs prev closeShareBenzinga - 10.2Regular26.10.02 22:30
●●●●●●●● ●●●●● ●●●●●●
Climb Bio announced it will present new clinical data for its kidney disease drug candidates, CLYM116 and budoprutug, at the upcoming ASN Kidney Week 2026. While the presentation highlights progress in its pipeline, the long-term clinical efficacy remains to be fully validated.…more
$10.34+1.62%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report